The impact of pharmacogenomics in personalized medicine
DB Singh - Current Applications of Pharmaceutical Biotechnology, 2020 - Springer
Recent advances in Pharmacogenomics have made it possible to understand the reasons
behind the different response of a drug. Discovery of genetic variants and its association …
behind the different response of a drug. Discovery of genetic variants and its association …
Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in …
J Adiwidjaja, AV Boddy, AJ McLachlan - Frontiers in Pharmacology, 2020 - frontiersin.org
Long-term use of imatinib is effective and well-tolerated in children with chronic myeloid
leukaemia (CML) yet defining an optimal dosing regimen for imatinib in younger patients is a …
leukaemia (CML) yet defining an optimal dosing regimen for imatinib in younger patients is a …
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update
Despite the excellent efficacy and improved clinical responses obtained with imatinib
mesylate (IM), development of resistance in a significant proportion of chronic myeloid …
mesylate (IM), development of resistance in a significant proportion of chronic myeloid …
Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens
J Adiwidjaja, AS Gross, AV Boddy… - British Journal of …, 2022 - Wiley Online Library
Aims This study implements a physiologically‐based pharmacokinetic (PBPK) modelling
approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing …
approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing …
Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
JA Adattini, J Adiwidjaja, AS Gross… - Pharmacology …, 2023 - Wiley Online Library
We aimed to use physiologically based pharmacokinetic (PBPK) modeling and simulation to
predict imatinib steady‐state plasma exposure in patients with chronic myeloid leukemia …
predict imatinib steady‐state plasma exposure in patients with chronic myeloid leukemia …
Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a …
J Adiwidjaja, AV Boddy… - British Journal of Clinical …, 2020 - Wiley Online Library
Aims This study aimed to investigate the potential interaction between Schisandra
sphenanthera, imatinib and bosutinib combining in vitro and in silico methods. Methods In …
sphenanthera, imatinib and bosutinib combining in vitro and in silico methods. Methods In …
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
J Adiwidjaja, AV Boddy, AJ McLachlan - European Journal of Clinical …, 2022 - Springer
Purpose This study implements a physiologically based pharmacokinetic (PBPK) modelling
approach to predict the effect of hydrastine and berberine, two major alkaloids present in …
approach to predict the effect of hydrastine and berberine, two major alkaloids present in …
The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats
Background Imatinib is mainly metabolized by CYP3A4 and to a lesser extent by other
isoenzymes, with N-desmethyl imatinib being its major equipotent metabolite. Being a …
isoenzymes, with N-desmethyl imatinib being its major equipotent metabolite. Being a …
Physiologically based pharmacokinetic modeling approaches for patients with SARS‐CoV‐2 Infection: a case study with imatinib
J Adiwidjaja, JA Adattini, AV Boddy… - The Journal of …, 2022 - Wiley Online Library
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which causes
coronavirus disease 2019 (COVID‐19), manifests as mild respiratory symptoms to severe …
coronavirus disease 2019 (COVID‐19), manifests as mild respiratory symptoms to severe …
Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic …
SA Mangoura, MH Abdel-Raheem, HA Eltyb… - Cancer Chemotherapy …, 2025 - Springer
Purpose The treatment landscape for chronic myeloid leukemia (CML) has been
revolutionized by the introduction of imatinib, a tyrosine kinase inhibitor, which has …
revolutionized by the introduction of imatinib, a tyrosine kinase inhibitor, which has …